New therapeutical strategies in the treatment of metastatic disease

Dermatologic Therapy

Volumn 25, Issue 5, 2012, Pages 452-457

  Julia, Fanny ^a   Thomas, Luc ^a   Dalle, Stéphane ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

B raf inhibitor; c KIT inhibitor; ipilimumab; mechanisms of resistance; melanoma; targeted therapy

Indexed keywords

B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; IMATINIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; VEMURAFENIB;

ALOPECIA; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOPATHOLOGY; INOPERABLE CANCER; KERATOACANTHOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PRURITUS; SKIN CARCINOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; EUROPE; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867362051     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01487.x     Document Type: Article

References (40)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009: 27: 6199-6206.
2. Flaherty KT, Yasothan U, Kirkpatrick P,. Vemurafenib. Nat Rev Drug Discov 2011: 10: 811-812.
3. Eggermont AM, Robert C,. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011: 47: 2150-2157.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002: 417: 949-954.
5. Gray-Schopfer V, Wellbrock C, Marais R,. Melanoma biology and new targeted therapy. Nature 2007: 445: 851-857.
6. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010: 464: 431-435.
7. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010: 140: 209-221.
8. Dhomen N, Marais R,. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009: 23: 529-545.
9. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009: 41: 544-552.
10. Dhomen N, Reis-Filho JS, da, Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009: 15: 294-303.
11. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006: 95: 581-586.
12. Amaravadi RK, Schuchter LM, McDermott DF, et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009: 15: 7711-7718.
13. McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008: 26: 2178-2185.
14. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009: 27: 2823-2830.
15. Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010: 70: 5518-5527.
16. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010: 363: 809-819.
17. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011: 29 (Suppl.): abstr 8509.
18. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011: 364: 2507-2516.
19. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010: 468: 973-977.
20. Dalle S, Poulalhon N, Thomas L,. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011: 365: 1448-1449; author reply 1450.
21. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011: 16: 2450-2457.
22. Arkenau HT, Kefford R, Long GV,. Targeting BRAF for patients with melanoma. Br J Cancer 2011: 104: 392-398.
23. Alexeev V, Yoon K,. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006: 126: 1102-1110.
24. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004: 22: 4514-4522.
25. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006: 24: 4340-4346.
26. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005: 353: 2135-2147.
27. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008: 99: 734-740.
28. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005: 92: 1398-1405.
29. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006: 106: 2005-2011.
30. Lutzky J, Bauer J, Bastian BC,. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008: 21: 492-493.
31. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P,. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008: 5: 737-740.
32. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011: 29: 2904-2909.
33. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007: 12: 873-883.
34. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP,. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009: 206: 1717-1725.
35. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010: 11: 155-164.
36. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008: 26: 5950-5956.
37. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010: 363: 711-723.
38. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L,. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009: 218: 69-70.
39. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011: 29: 489-498.
40. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011: 364: 2517-2526.